Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer

Abstract

Preoperative window therapy with gefitinib is a safe and feasible regimen in early NSCLC and provides a trial design that may better inform predictors of treatment response or sensitivity.